Zacks: Brokerages Anticipate Integra LifeSciences Holdings Co. (NASDAQ:IART) Will Post Earnings of $0.68 Per Share

Wall Street analysts expect Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) to report $0.68 earnings per share (EPS) for the current quarter, Zacks reports. Six analysts have made estimates for Integra LifeSciences’ earnings, with estimates ranging from $0.67 to $0.70. Integra LifeSciences reported earnings of $0.69 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.4%. The firm is expected to issue its next earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Integra LifeSciences will report full year earnings of $3.30 per share for the current financial year, with EPS estimates ranging from $3.28 to $3.32. For the next year, analysts forecast that the business will post earnings of $3.69 per share, with EPS estimates ranging from $3.54 to $3.99. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Integra LifeSciences.

Integra LifeSciences (NASDAQ:IARTGet Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The life sciences company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.83 by $0.01. The firm had revenue of $405.52 million for the quarter, compared to analysts’ expectations of $403.41 million. Integra LifeSciences had a net margin of 10.96% and a return on equity of 16.93%. Integra LifeSciences’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.84 earnings per share.

Several analysts have issued reports on the company. StockNews.com upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Thursday, March 24th. Bank of America boosted their price objective on Integra LifeSciences from $55.00 to $65.00 and gave the stock an “underperform” rating in a report on Tuesday, January 18th. Truist Financial downgraded Integra LifeSciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $72.00 to $71.00 in a report on Wednesday. Finally, Piper Sandler cut their price objective on Integra LifeSciences from $72.00 to $66.00 in a report on Wednesday, February 23rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $75.56.

NASDAQ IART opened at $62.68 on Friday. The stock’s 50-day moving average price is $65.21 and its two-hundred day moving average price is $66.55. The company has a current ratio of 3.39, a quick ratio of 2.46 and a debt-to-equity ratio of 0.89. The company has a market cap of $5.21 billion, a PE ratio of 31.66, a PEG ratio of 2.01 and a beta of 1.14. Integra LifeSciences has a 1 year low of $61.50 and a 1 year high of $77.40.

In related news, major shareholder Tru St Partnership, L.P. sold 150,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 23rd. The stock was sold at an average price of $64.67, for a total value of $9,700,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Glenn Coleman sold 6,268 shares of the business’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $66.04, for a total value of $413,938.72. Following the completion of the sale, the chief operating officer now directly owns 41,288 shares of the company’s stock, valued at approximately $2,726,659.52. The disclosure for this sale can be found here. Insiders sold a total of 231,268 shares of company stock worth $15,050,939 in the last quarter. 4.20% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Eaton Vance Management boosted its position in Integra LifeSciences by 2.6% during the fourth quarter. Eaton Vance Management now owns 4,107,343 shares of the life sciences company’s stock worth $275,029,000 after purchasing an additional 103,505 shares during the period. Alliancebernstein L.P. boosted its position in Integra LifeSciences by 11.0% during the fourth quarter. Alliancebernstein L.P. now owns 2,329,360 shares of the life sciences company’s stock worth $156,044,000 after purchasing an additional 231,383 shares during the period. Goldman Sachs Group Inc. boosted its position in Integra LifeSciences by 73.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,482,718 shares of the life sciences company’s stock worth $99,327,000 after purchasing an additional 629,202 shares during the period. Dimensional Fund Advisors LP boosted its position in Integra LifeSciences by 2.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,356,159 shares of the life sciences company’s stock worth $90,853,000 after purchasing an additional 31,192 shares during the period. Finally, Geode Capital Management LLC boosted its position in Integra LifeSciences by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 1,006,447 shares of the life sciences company’s stock worth $67,421,000 after purchasing an additional 57,231 shares during the period. 90.98% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile (Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Recommended Stories

Get a free copy of the Zacks research report on Integra LifeSciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.